Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsIndependent Health Step Therapy Prior Auth | OpenP…
    Ask Trek AI about this page
    CurrentIndependent HealthPolicy N/A

    Step Therapy Criteria — Medicare Advantage Part D Formularies

    Customize your policy alerts

    Sign up for all Independent Health policy alerts

    Know when Independent Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines step therapy protocols requiring trial of specified first-line drugs before coverage of listed products for Independent Health's 2026 Medicare Advantage Part D formulary members. Applies to providers prescribing the listed drugs for affected Medicare Advantage C-SNP Part D members.

    Policy Summary
    PayerIndependent Health
    PolicyStep Therapy Criteria — Medicare Advantage Part D Formularies
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJun 1, 2026
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionObtain and document trial and failure or intolerance of the specified first-line drug(s) listed for each product before requesting coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    13
    distinct products or product groups listed
    MA C‑SNP Part Dformulary affected
    Requires prior trialmost entries require trial of an alternative first

    Coverage Criteria for Affected Products

    Aliskiren 300 mg initial criteria

    Covered when ALL of the following are met:

    Aliskiren 300 mg step: Member has tried and had inadequate response or intolerance to an angiotensin-II receptor blocker (ARB)trial of ARB

    Supports coverage of aliskiren 300 mg after ARB failure

    Aripiprazole formulation sequencing

    Covered when ALL of the following are met:

    Aripiprazole ODT: Member has tried and had inadequate response or intolerance to aripiprazole oral solutiontrial of oral solution

    ODT requires prior solution

    Aripiprazole film: Member has tried and had inadequate response or intolerance to aripiprazole ODTtrial of ODT

    Film requires prior ODT

    EUCRISA

    Covered when ALL of the following are met:

    EUCRISA ointment: Member has tried and had inadequate response or intolerance to a topical corticosteroid or a topical calcineurin inhibitortrial of topical steroid or topical calcineurin inhibitor

    Either class acceptable as first-line topical therapy

    Febuxostat

    Covered when ALL of the following are met:

    Febuxostat (40 mg and 80 mg): Member has tried and had inadequate response or intolerance to allopurinoltrial of allopurinol

    All febuxostat strengths require prior allopurinol

    SYMPAZAN films

    Covered when ALL of the following are met:

    SYMPAZAN films: Member has tried and had inadequate response or intolerance to clobazam oral suspensiontrial of clobazam suspension

    All SYMPAZAN film strengths require prior clobazam suspension

    TRELSTAR MixJect

    Covered when ALL of the following are met:

    TRELSTAR MixJect: Member has tried and had inadequate response or intolerance to Lupron Depottrial of Lupron Depot

    Applies to listed MixJect strengths

    Versacloz and doxercalciferol

    Covered when ALL of the following are met:

    Versacloz suspension: Member has tried and had inadequate response or intolerance to clozapine ODTtrial of clozapine ODT

    Supports coverage of Versacloz suspension

    Doxercalciferol: Member has tried and had inadequate response or intolerance to calcitrioltrial of calcitriol

    All listed doxercalciferol strengths require prior calcitriol

    This policy does not list any product-level exclusions beyond the step therapy sequencing requirements described for specific drugs. It applies to the Independent Health 2026 Medicare Advantage C‑SNP Part D formulary and defines step therapy expectations that must be met before coverage is approved for the listed products.

    Provider Requirements and Documentation

    Prior Authorization

    Step therapy prior authorization requirement

    Prior authorization requires documentation of trial and inadequate response or intolerance to the specified first-line drug(s) listed for each affected product before coverage of the requested product.

    Step Therapy

    Aliskiren 300 mg requires ARB first

    Aliskiren fumarate 300 mg requires a prior trial of an angiotensin-II receptor blocker (ARB) before coverage is approved.

    Step Therapy

    Aripiprazole ODT/film sequencing

    Aripiprazole ODT requires prior use of aripiprazole oral solution; aripiprazole oral films require prior use of aripiprazole ODT before coverage.

    Key Definitions

    Step Therapy — definition and key facts
    DefinitionA protocol requiring trial of specified initial drug(s) before coverage of alternative drug(s) for the same condition.
    PurposeEnsures clinically appropriate first‑line therapies are tried and documented before higher‑tier or alternative agents are covered on the Medicare Advantage C‑SNP Part D formulary.
    Provider requirementPrior authorization must document trial and inadequate response or intolerance to the specified first‑line drug(s) listed for the requested product.
    Applies toSelect products listed in this policy (e.g., aliskiren 300 mg, aripiprazole ODT/films, EUCRISA ointment, febuxostat, SYMPAZAN films, TRELSTAR MixJect, VERSACLOZ, doxercalciferol).
    Effective date2026-06-01 (policy list current as of 6/1/2026).

    Initial Therapy Requirements

    Initial therapy requirements

    Initial step therapy requirements for listed drugs

    Aliskiren 300 mg initial requirement: Requires prior ARB trialtrial of ARB

    Applies to aliskiren 300 mg only

    Step Therapy Matrix

    Requested drugRequired prior therapyCoverage status
    aliskiren fumarate tablet 300 mg oral
    Trial and inadequate response or intolerance to an angiotensin-II receptor blocker (ARB)
    Covered with step therapy requirement: ARB first
    Requested drug/formulationRequired prior formulationCoverage status
    Aripiprazole orally-disintegrating tablet (ODT)
    Aripiprazole oral solution (trial and inadequate response or intolerance)
    Covered with step therapy requirement: solution before ODT
    Aripiprazole oral film
    Aripiprazole ODT (trial and inadequate response or intolerance)
    Covered with step therapy requirement: ODT before film
    Requested drugRequired prior therapyCoverage status
    EUCRISA ointment 2%
    Trial and inadequate response or intolerance to either a topical corticosteroid or a topical calcineurin inhibitor
    Covered with step therapy requirement: topical steroid or topical calcineurin inhibitor first
    Requested drug (strengths)Required prior therapyCoverage status
    febuxostat tablet 40 mg; febuxostat tablet 80 mg
    Trial and inadequate response or intolerance to allopurinol
    Covered with step therapy requirement: allopurinol first
    Requested drug (strengths)Required prior therapyCoverage status
    SYMPAZAN film (5 mg, 10 mg, 20 mg)
    Trial and inadequate response or intolerance to clobazam oral suspension
    Covered with step therapy requirement: clobazam oral suspension first
    Requested drug (MixJect strengths)Required prior therapyCoverage status
    TRELSTAR MixJect suspension (3.75 mg; 11.25 mg; 22.5 mg recon)
    Trial and inadequate response or intolerance to Lupron Depot
    Covered with step therapy requirement: Lupron Depot first
    Requested drugRequired prior therapyCoverage status
    VERSACLOZ suspension 50 mg/mL
    Trial and inadequate response or intolerance to clozapine orally-disintegrating tablet (ODT)
    Covered with step therapy requirement: clozapine ODT first
    Doxercalciferol capsules (0.5 mcg, 1 mcg, 2.5 mcg)
    Trial and inadequate response or intolerance to calcitriol
    Covered with step therapy requirement: calcitriol first

    Background and Rationale

    Step therapy (fail‑first) requires a trial of a clinically appropriate first‑line therapy specified in this document before the requested alternative product will be covered. The intent is to ensure members try standard, lower‑tier, or formulary preferred agents first and to permit coverage of the requested drug only when the member has had an inadequate response or intolerance to the required prior therapy. Providers must document the prior trial and the outcome when submitting a prior authorization request.

    Policy Summary
    PayerIndependent Health
    PolicyStep Therapy Criteria — Medicare Advantage Part D Formularies
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJun 1, 2026
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionObtain and document trial and failure or intolerance of the specified first-line drug(s) listed for each product before requesting coverage.
    SourceLink
    On This Page
    Coverage Criteria for Affected ProductsProvider Requirements and DocumentationKey DefinitionsInitial Therapy RequirementsStep Therapy MatrixBackground and Rationale
    Step Therapy

    EUCRISA requires topical steroid or calcineurin inhibitor first

    EUCRISA ointment 2% requires prior use of either a topical corticosteroid or a topical calcineurin inhibitor before coverage.

    Step Therapy

    Febuxostat requires allopurinol first

    Febuxostat tablets (40 mg and 80 mg) require documented prior use of allopurinol before coverage will be granted.

    Step Therapy

    SYMPAZAN films require clobazam suspension first

    SYMPAZAN films (all strengths listed) require prior use of clobazam oral suspension before coverage.

    Step Therapy

    TRELSTAR requires Lupron Depot first

    TRELSTAR MixJect formulations require prior use of Lupron Depot before coverage of the MixJect products.

    Step Therapy

    Versacloz and doxercalciferol sequencing

    VERSACLOZ suspension requires prior use of clozapine ODT; doxercalciferol capsules require prior use of calcitriol before coverage.

    Documentation Required

    Aliskiren 300 mg documentation

    Document the prior trial and the outcome (inadequate response or intolerance) of ARB therapy when requesting coverage for aliskiren fumarate 300 mg.

    Documentation Required

    Aripiprazole sequencing documentation

    Document prior use of aripiprazole oral solution before approving aripiprazole ODT, and document prior use of aripiprazole ODT before approving aripiprazole oral films.

    Documentation Required

    EUCRISA documentation

    Document prior use of a topical corticosteroid or a topical calcineurin inhibitor when requesting coverage for EUCRISA ointment 2%.

    Documentation Required

    Febuxostat documentation

    Document prior use of allopurinol (trial and outcome) for requests for febuxostat tablets (40 mg and 80 mg).

    Documentation Required

    SYMPAZAN documentation

    Document prior use of clobazam oral suspension for requests for SYMPAZAN films (all strengths).

    Documentation Required

    TRELSTAR documentation

    Document prior use of Lupron Depot (trial and outcome) for requests for TRELSTAR MixJect formulations.

    Documentation Required

    Versacloz and doxercalciferol documentation

    Document prior use of clozapine ODT for Versacloz suspension requests and prior use of calcitriol for doxercalciferol capsule requests.

    Denial Risk

    Aliskiren 300 mg denial risk

    Coverage for aliskiren fumarate 300 mg requires prior use of an angiotensin-II receptor blocker (ARB); failure to document a prior ARB trial may result in denial.

    Denial Risk

    Aripiprazole ODT/film sequencing denial risk

    Coverage for aripiprazole ODT and films requires documented trials of the specified prior formulations (oral solution before ODT, ODT before film); lack of those prior trials may lead to denial.

    Denial Risk

    EUCRISA denial risk

    Coverage for EUCRISA ointment requires prior use of a topical corticosteroid or topical calcineurin inhibitor; absence of such a trial may risk denial.

    Denial Risk

    Febuxostat denial risk

    Coverage for febuxostat tablets (40 mg and 80 mg) requires prior use of allopurinol; failure to document prior allopurinol use may trigger denial.

    Denial Risk

    SYMPAZAN denial risk

    Coverage for SYMPAZAN films requires prior use of clobazam oral suspension; absence of documentation of prior clobazam suspension use may result in denial.

    Denial Risk

    TRELSTAR denial risk

    Coverage for TRELSTAR MixJect formulations requires prior use of Lupron Depot; lack of prior Lupron Depot use may cause denial.

    Denial Risk

    Versacloz and doxercalciferol sequencing denial risk

    Coverage for VERSACLOZ suspension requires prior use of clozapine ODT and coverage for doxercalciferol capsules requires prior use of calcitriol; missing documentation of these prior therapies may lead to denial.